ABCL Stock Analysis: Abcellera Biologics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 3.914m USD | 12M Return: 107.1% | CA00288U1066 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 51.3M
Qual. Beats: 0
Rev. Trend: 47.6%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
Seasonality 5.8 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
AbCellera Biologics Inc. (NASDAQ: ABCL) is a Canadian biotechnology company headquartered in Vancouver that focuses on discovering and developing antibody-based medicines for indications with unmet medical need, primarily in the United States. The company operates in the biotechnology sub-industry of the health care sector and uses an antibody discovery platform to advance its own pipeline while partnering with major pharmaceutical firms.
The companys lead clinical assets include ABCL635, a non-hormonal medicine currently in Phase 2 trials for moderate-to-severe vasomotor symptoms, and ABCL575, a fully human, half-life extended monoclonal antibody in Phase 1 development for T-cell-mediated autoimmune conditions such as atopic dermatitis. Beyond its internal pipeline, AbCellera pursues a partnership-driven business model, maintaining research, development, and licensing agreements with Eli Lilly, AbbVie, Jazz Pharmaceuticals, Biogen, and Vertex Pharmaceuticals, among others, to co-develop multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions.
Founded in 2012 and publicly listed since its December 2020 IPO, AbCellera combines internal drug development with a collaboration-heavy revenue approach, leveraging its antibody technology platform across multiple therapeutic areas and partners.
- ABCL635 Phase 2 vasomotor symptom trial readout
- Partnership revenue from Lilly and AbbVie collaborations
- Cash burn rate on preclinical pipeline expansion
| Net Income: -164.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.11 > 0.02 and ΔFCF/TA -4.49 > 1.0 |
| NWC/Revenue: 946.1% < 20% (prev 2.05k%; Δ -1.11k% < -1%) |
| CFO/TA -0.12 > 3% & CFO -154.7m > Net Income -164.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 12.77 > 1.5 & < 3 |
| Outstanding Shares: last quarter (305.6m) vs 12m ago 2.36% < -2% |
| Gross Margin: 56.45% > 18% (prev -209.5%; Δ 265.9% > 0.5%) |
| Asset Turnover: 4.88% > 50% (prev 2.34%; Δ 2.54% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.48 (Total Current Assets 679.2m - Total Current Liabilities 53.2m) / Total Assets 1.31b |
| B: -0.10 (Retained Earnings -128.1m / Total Assets 1.31b) |
| C: -0.15 (EBIT TTM -201.6m / Avg Total Assets 1.35b) |
| D: 2.18 (Book Value of Equity 896.0m / Total Liabilities 411.6m) |
| Altman-Z'' = 4.11 = AA |
| DSRI: 0.31 (Receivables 95.4m/153.4m, Revenue 66.2m/32.9m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: -1.25 (AQ_t -0.21 / AQ_t-1 0.17) |
| SGI: 2.01 (Revenue 66.2m / 32.9m) |
| TATA: -0.01 (NI -164.7m - CFO -154.7m) / TA 1.31b) |
| Beneish M = -4.20 (Cap -4..+1) = AAA |
As of November 03, 2026, the stock is trading at USD 11.12 with a total of 3,010,246 shares traded. Over the past week, the price has changed by -7.95%, over one month by -19.07%, over three months by +90.74% and over the past year by +107.08%.
Current recommended Stop Loss: 10.00 (which is 10.1% or 1.3 ATR below the current price).
Abcellera Biologics has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy ABCL.
- StrongBuy: 9
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 16.8 | 51.3% |
P/E Forward = 27.5482
P/S = 59.1581
P/B = 4.2765
Revenue TTM = 66.2m USD
EBIT TTM = -201.6m USD
EBITDA TTM = -169.0m USD
Long Term Debt = 129.9m USD (estimated: total debt 135.6m - short term 5.67m)
Short Term Debt = 5.67m USD (from shortTermDebt, last quarter)
Debt = 135.6m USD (from shortLongTermDebtTotal, last quarter) (leases 135.6m already included)
Net Debt = -404.5m USD (calculated: Debt 135.6m - CCE 540.1m)
Enterprise Value = 3.51b USD (3.91b + Debt 135.6m - CCE 540.1m)
Interest Coverage Ratio = unknown (Ebit TTM -201.6m / Interest Expense TTM 0.0)
EV/FCF = -23.58x (Enterprise Value 3.51b / FCF TTM -148.9m)
FCF Yield = -4.24% (FCF TTM -148.9m / Enterprise Value 3.51b)
FCF Margin = -225.0% (FCF TTM -148.9m / Revenue TTM 66.2m)
Net Margin = -248.8% (Net Income TTM -164.7m / Revenue TTM 66.2m)
Gross Margin = 56.45% ((Revenue TTM 66.2m - Cost of Revenue TTM 28.8m) / Revenue TTM)
Gross Margin QoQ = none% (prev -4.09%)
Tobins Q-Ratio = 2.68 (Enterprise Value 3.51b / Total Assets 1.31b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 135.6m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -159.2m (EBIT -201.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 10.40 (Total Current Assets 679.2m / Total Current Liabilities 65.3m)
Debt / Equity = 0.15 (Debt 135.6m / totalStockholderEquity, last quarter 896.0m)
Debt / EBITDA = 2.39 (negative EBITDA) (Net Debt -404.5m / EBITDA -169.0m)
Debt / FCF = 2.72 (negative FCF - burning cash) (Net Debt -404.5m / FCF TTM -148.9m)
Total Stockholder Equity = 941.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -12.15% (Net Income -164.7m / Total Assets 1.31b)
RoE = -17.49% (Net Income TTM -164.7m / Total Stockholder Equity 941.3m)
RoCE = -18.82% (EBIT -201.6m / Capital Employed (Equity 941.3m + L.T.Debt 129.9m))
RoIC = -12.67% (negative operating profit) (NOPAT -159.2m / Invested Capital 1.26b)
WACC = 13.91% (E(3.91b)/V(4.05b) * Re(14.39%) + D(135.6m)/V(4.05b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 14.39% (= CAPM, Blume Beta Adj.) -> capped to 12.54%
Shares (quarterly) Correlation: 95.22 | Cagr: 1.93%
[DCF] Fair Price = unknown (Cash Flow -148.9m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.19 | # QB: 0
Revenue Correlation: 47.58 | Revenue CAGR: 23.16% | SUE: -0.28 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.18 | Chg30d=-4.47% | Revisions=+25% | Analysts=6
EPS current Year (2026-12-31): EPS=-0.67 | Chg30d=-0.87% | Revisions=-29% | GrowthEPS=-37.6% | GrowthRev=-64.9%
EPS next Year (2027-12-31): EPS=-0.76 | Chg30d=+0.20% | Revisions=+17% | GrowthEPS=-13.1% | GrowthRev=+7.1%
[Analyst] Revisions Ratio: +0% (up=4, down=4)